The latest

News

Marco Lobba and Sophia Lugo

Marco Lobba and Sophia Lugo Named to San Francisco Business Times 40 Under 40

Many people don’t end up in the jobs they wanted when they were four years old. But Catena Biosciences CEO Marco Lobba and Radar Therapeutics CEO Sophia Lugo aren’t most people — a fact that didn’t escape the San Francisco Business Times. For their innovative contributions to biotech and precision medicine — Lobba with CatenaBio’s Multi-Payload Conjugate™ antibody-drug combinations, Lugo with Radar’s targeted mRNA therapies — the SF Business Times named both Lobba and Lugo to their 2025 “40 Under 40” class of honorees, recognizing them as two of the most influential and industrious leaders in the Bay Area. The awards will be presented on Friday, April 25 at the Westin St. Francis in San Francisco.

Latest news171

A view of the skylights at BBH

A Brutalist Icon in Berkeley Is Reborn as a Bioresearch Hub

“I still can’t believe that I was able to work on the building, be part of the legacy,” said Kevin Koblik, project manager for MBH Architects, the firm that headed the conversion effort. “It was a challenge start to finish, but in all the right ways.” Read post
An interior view of BBH's skylights

A First Look Inside UC Berkeley’s Bakar BioEnginuity Hub

“We always intended Bakar Labs to have a ‘double bottom line,’ a responsibility to select and support startups that have a strong chance of market success and are developing solutions to make the world a better place,” said Regis Kelly, director of Bakar Labs and QB3 executive director. Read post